What top creators are saying about Spyre Therapeutics, Inc.(SYRE)

Clinical-stage biotechnology company developing antibody treatments for inflammatory and autoimmune diseases

2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.

Creator sentiment — last 30 days

Not enough scored insights about Spyre Therapeutics, Inc. in the last 30 days yet.

Top creators covering Spyre Therapeutics, Inc. (SYRE)

The 1 sources with the most insights about Spyre Therapeutics, Inc. on Kazuha.

Latest insights about Spyre Therapeutics, Inc. (SYRE)

AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.

Wednesday, October 7, 2026

Neutral

Mentioned in connection with an offering; no view on the stock was provided.

Tuesday, September 22, 2026

Slightly Bullish
Target: No price target mentioned; an estimated share price of about $90 was discussed

The speaker cited approximately $1.1 billion in cash, no debt, and an estimated enterprise value of about $6.8 billion, but gave no clear recommendation; the investment case depends on pipeline and trial progress.

Discussed alongside Spyre Therapeutics, Inc. (SYRE)

Other assets that creators frequently mention in the same content as Spyre Therapeutics, Inc..

Frequently asked

Which podcasters and creators cover Spyre Therapeutics, Inc. (SYRE) the most?

The most active sources covering Spyre Therapeutics, Inc. (SYRE) on Kazuha are @theshkrelipill. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.

How many insights about Spyre Therapeutics, Inc. (SYRE) are on Kazuha?

Kazuha has indexed 2 AI-extracted insights about Spyre Therapeutics, Inc. (SYRE) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.

What other assets do creators discuss alongside Spyre Therapeutics, Inc. (SYRE)?

Creators covering Spyre Therapeutics, Inc. (SYRE) most frequently also discuss META, SNDK, ASML, AMD, MU. See the "Discussed alongside" section above for full asset pages.